FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to compounds of formula 1a:
, wherein: A means CH=CH orS; R23 means hydrogen, halogen, (C1-C4)-alkyl, (C1-C4)-alkyloxy or (C1-C4)-alkyl-S-; R24 means hydrogen or halogen when A means CH=CH or hydrogen, halogen, (C1-C4)-alkyl when A means S; X means N(H)C=O, N(H)S(O)2, C=ON(H) or S(O)2N(H); Y means C(R12)=C(R13), N=C(R14) or C(R15)=N, or condensed optionally substituted 5-7-member carbocyclyl; R12 means hydrogen, halogen, (C1-C10)-alkyl, (C2-C10)-alkenyl, (C3-C6)-cycloalkyloxy, (C3-C10)-cycloalkenyloxy, (C3-C6)-cycloalkyl, (C3-C10)-cycloalkenyl, (C3-C6)-cycloalkyl[(C1-C4)-alkyl or (C2-C4)-alkenyl], (C3-C6)-cycloalkyl (C1-C4)-alkyloxy, (C1-C10)-alkyloxy, (C3-C10)-alkenyloxy, (C1-C10)-alkyl-S-, cyano, (C1-C10)-alkylcarbonyl- or phenyl; R13 means hydrogen, halogen or (C1)-alkyl; R14 means hydrogen or (C1-C3)-alkyl-S(O)m; R15 means hydrogen, halogen, (C1-C10)-alkyl, amino, [(C1-C10)-alkyl or (C2-C10)-alkenyl] amino, [(C1-C10)-alkyl or (C2-C10)-alkenyl]((C1-C10)-alkyl)amino or nitro; R21 means hydrogen; R22 means hydrogen, halogen, (C1)-alkyl, while Y means C(R12)=C(R13), N=C(R14) or C(R15)=N; R51 means COOH or CONH(R53); R53 means R55-SO2- or tetrazolyl; R55 means (C1-C4)-alkly; and m is equal to 0; wherein all specified phenyl groups may be independently substituted by one or more halogen atoms; wherein all specified alkyl groups may be independently substituted by one or more fluorine atoms; or its stereoisomer form, a mixture of stereoisomer forms in any ratio or its physiologically acceptable salt, provided the following compounds are excluded: 2-benzoylamino-2,3-dihydro-2-indencarboxylic acid; 2-(naphthalin-2-ylsulphonylamino)indane-2-carboxylic acid. Also, the invention refers to a pharmaceutical composition possessing CXCR5 receptor inhibitory activity on the basis of the compounds described above, as well as a method of treating a patient, involving introducing said compounds into the patient.
EFFECT: there are prepared and described the new compounds which possess CXCR5 inhibitory action and may be used for treating and preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, and Crohn's disease.
17 cl, 397 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATING SKIN DISEASES | 2009 |
|
RU2544011C2 |
| GLP-1 RECEPTOR AGONISTS AND USE THEREOF | 2017 |
|
RU2740135C1 |
| AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | 2004 |
|
RU2423363C2 |
| 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEINKINASE INHIBITORS | 2005 |
|
RU2379308C2 |
| FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | 2014 |
|
RU2671979C2 |
| PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | 2008 |
|
RU2464262C2 |
| NEW COMPOUNDS - NEUROKININ 1 RECEPTOR ANTAGONIZER | 2013 |
|
RU2631319C2 |
| POLYCYCLIC ANTAGONISTS OF TLR7/8 AND THEIR USE IN TREATMENT OF IMMUNE DISORDERS | 2016 |
|
RU2783748C2 |
| CONDENSED TRICYCLIC DERIVATIVES FOR TREATING PSYCHOTIC DISORDERS | 2005 |
|
RU2409582C2 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
